

Rachel Wong

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4754055/rachel-wong-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

2,838
citations

16
h-index

53
g-index

87
ext. papers

3,737
ext. citations

4.7
avg, IF

4.51
L-index

#	Paper	IF	Citations
79	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016 , 8, 346ra92	17.5	688
78	Guidelines for the management of oesophageal and gastric cancer. <i>Gut</i> , 2011 , 60, 1449-72	19.2	404
77	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 1715-22	10.3	373
76	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , 2012 , 30, 1620-7	2.2	293
75	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1710-1717	13.4	177
74	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. <i>Annals of Oncology</i> , 2011 , 22, 2042-2048	10.3	167
73	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019 , 68, 663-671	19.2	138
72	Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. <i>Annals of Oncology</i> , 2013 , 24, 1253-61	10.3	61
71	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018 , 57, 1438-1444	3.2	48
70	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021 , 39, 966-977	2.2	42
69	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e9-e15	3.8	37
68	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021 , 148, 1014-1026	7.5	26
67	Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. <i>Lancet, The</i> , 2007 , 369, 1923-4	40	23
66	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019 , 15, 567-577	3.6	18
65	Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape?. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 251-61	3.8	17
64	Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e569-e577	3.8	16
63	Optimising treatment regimens for the management of advanced gastric cancer. <i>Annals of Oncology</i> , 2009 , 20, 605-8	10.3	16

62	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003620	11.6	16
61	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 387-94	3.6	14
60	Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice. <i>Internal Medicine Journal</i> , 2015 , 45, 267-74	1.6	13
59	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3516-3516	2.2	13
58	Impact of Surgical Complications Following Resection of Locally Advanced Rectal Adenocarcinoma on Adjuvant Chemotherapy Delivery and Survival Outcomes. <i>Diseases of the Colon and Rectum</i> , 2016 , 59, 916-24	3.1	11
57	Treatment of metastatic colorectal cancer: focus on panitumumab. <i>Cancer Management and Research</i> , 2015 , 7, 189-98	3.6	11
56	Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. <i>Future Oncology</i> , 2018 , 14, 2725-2739	3.6	10
55	Survival impact of the Australian National Bowel Cancer Screening Programme. <i>Internal Medicine Journal</i> , 2016 , 46, 166-71	1.6	9
54	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019 , 145, 540-547	7.5	8
53	Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15131-e15131	2.2	8
52	Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. <i>Nutrition and Cancer</i> , 2019 , 71, 624-628	2.8	7
51	Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e125-32	3.8	7
50	Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 136-143	1.9	7
49	Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e593-e599	3.8	6
48	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e45-e54	3.8	6
47	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021 , 45, 100637	2.3	6
46	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 314-321	1.9	5
45	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019 , 49, 446-454	1.6	5

44	Resection of colorectal cancer liver metastases in older patients. <i>ANZ Journal of Surgery</i> , 2020 , 90, 796-801	4
43	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 262-71	1.9 3
42	Clinicians' Attitudes towards management of metastatic colorectal adenocarcinoma. <i>ANZ Journal of Surgery</i> , 2008 , 78, 454-60	1 3
41	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3511-3511	2.2 3
40	Bridging the gap: a pre-post feasibility study of embedding exercise therapy into a co-located cancer unit. <i>Supportive Care in Cancer</i> , 2021 , 29, 6701-6711	3.9 3
39	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. <i>Clinical Cancer Research</i> , 2021 , 27, 2159-2167	12.9 3
38	Emerging strategies in the initial management of locally advanced rectal cancer. <i>Future Oncology</i> , 2019 , 15, 2955-2965	3.6 2
37	Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 650-650	2.2 2
36	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020 , 38, 1263-1275	4.4 2
35	Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. <i>Internal Medicine Journal</i> , 2020 ,	1.6 2
34	Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer. <i>Internal Medicine Journal</i> , 2021 , 51, 1262-1268	1.6 2
33	Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). <i>Radiotherapy and Oncology</i> , 2021 , 155, 27-32	5.3 2
32	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , 2021 , 16, 227-236	5 2
31	Impact of primary tumor stage on survival following resection of metachronous liver and/or lung metastases in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3557-3557	2.2 1
30	Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 682-682	2.2 1
29	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 750-750	2.2 1
28	Real-world survival outcomes of using neoadjuvant chemotherapy in pancreatic cancer patients: Findings from the PURPLE clinical registry.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16755-e16755	2.2 1
27	Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. <i>Acta Oncologica</i> , 2021 , 60, 482-490	3.2 1

26	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. <i>Pharmacoeconomics</i> , 2021 , 39, 953-964	4.4	1
25	Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer. <i>Acta Oncologica</i> , 2021 , 60, 1106-1113	3.2	1
24	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. <i>Internal Medicine Journal</i> , 2020 , 50, 165-172	1.6	1
23	Dose modification for haematological toxicity: a survey of Australian medical oncologists. <i>Internal Medicine Journal</i> , 2020 , 50, 1338-1343	1.6	0
22	Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting. <i>International Journal of Cancer</i> , 2021 , 149, 409-419	7.5	0
21	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021 , 20, e21-e34	3.8	0
20	How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, e167-e174	1.9	
19	ASPECCT: panitumumab versus cetuximab for colorectal cancer. <i>Lancet Oncology</i> , 2014 , 15, e302-3	21.7	
18	Less Surgery, Improved Survival From Stage IV Colorectal Cancer?. <i>JAMA Surgery</i> , 2015 , 150, 818-9	5.4	
17	Re: The developing clinical problem of chemotherapy-induced hepatic injury. <i>ANZ Journal of Surgery</i> , 2012 , 82, 569	1	
16	What is the impact of biologicals in colorectal cancer?. <i>Targeted Oncology</i> , 2008 , 3, 59-69	5	
15	European Society for Medical Oncology Invests in the Next Generation of Asia-Pacific Oncology Leaders. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020 , 41, 7-8	0.2	
14	Assessing real-world outcomes in metastatic colorectal cancer with KRASG12C mutation.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16072-e16072	2.2	
13	Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. <i>Growth Factors</i> , 2020 , 38, 127-136	1.6	
12	Association between type 2 diabetes mellitus (T2DM), diabetic therapies and clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14637-e14637	2.2	
11	Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14648-e14648	2.2	
10	Use and impact of bevacizumab in patients undergoing liver resection for metastatic colorectal cancer in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 698-698	2.2	
9	Use and impact of selective internal radiation therapy (SIRT) in routine care patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 742-742	2.2	

- 8 A phase II study of oxaliplatin/5FU/bevacizumab and concurrent pelvic radiation in patients with simultaneous primary and metastatic rectal cancer: The Chrome-B trial.. *Journal of Clinical Oncology* , **2016**, 34, 3613-3613 2.2
- 7 Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2017**, 35, 728-728 2.2
- 6 Small bowel adenocarcinoma treatment: A single centre experience.. *Journal of Clinical Oncology*, **2017**, 35, 451-451 2.2
- 5 Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, 738-738 2.2
- 4 Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2017**, 35, 785-785 2.2
- 3 The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. *Journal of Clinical Oncology*, **2012**, 30, e14088-e14088 2.2
- 2 Squamous cell carcinoma of unknown primary masquerading as multiple splenic abscesses. *ANZ Journal of Surgery*, **2019**, 89, 606-607 1
- 1 Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. *Current Problems in Cancer*, **2021**, 100793 2.3